ISLET-CELL ANTIBODIES, BUT NOT GLUTAMIC-ACID DECARBOXYLASE ANTIBODIES, ARE DECREASED BY PLASMAPHERESIS IN PATIENTS WITH NEWLY-DIAGNOSED INSULIN-DEPENDENT DIABETES-MELLITUS

Citation
G. Sundkvist et al., ISLET-CELL ANTIBODIES, BUT NOT GLUTAMIC-ACID DECARBOXYLASE ANTIBODIES, ARE DECREASED BY PLASMAPHERESIS IN PATIENTS WITH NEWLY-DIAGNOSED INSULIN-DEPENDENT DIABETES-MELLITUS, The Journal of clinical endocrinology and metabolism, 78(5), 1994, pp. 1159-1165
Citations number
50
Categorie Soggetti
Endocrynology & Metabolism
ISSN journal
0021972X
Volume
78
Issue
5
Year of publication
1994
Pages
1159 - 1165
Database
ISI
SICI code
0021-972X(1994)78:5<1159:IABNGD>2.0.ZU;2-W
Abstract
The effects of plasmapheresis on islet autoantibody levels, C-peptide (beta-cell function), and hemoglobin-A(1c) (HbA(1c); metabolic control ) were tested in a prospective blinded study of 18 newly diagnosed ins ulin-dependent diabetes mellitus (IDDM) patients randomly assigned to receive plasmapheresis (P), carried out as double filtration, or sham (S) treatment at diagnosis and 3 months thereafter. At diagnosis, 6 of 8 patients (75%) in group P and 9 of 10 patients (90%) in group S had islet cell antibodies (ICA), whereas 4 of 8 (50%) and 7 of 10 (70%) p atients, respectively, had glutamic acid decarboxylase antibodies (GAD 65-Ab), with no significant differences between the groups in ICA and GAD65-Ab levels. After 6 months, P patients showed significantly lower ICA levels than S patients (11 +/- 6 and 128 +/- 47 Juvenile Diabetes Foundation International Units, respectively; P < 0.02) due to an inc rease in ICA levels in 8 of 9 (88%) of the S patients not seen in P pa tients (P < 0.002). Concurrently, HbA1c stabilized in P, but not in S, patients and was significantly lower by 24 months (6.58 +/- 0.54% us. 9.76 +/- 1.21%; P < 0.05). Moreover, fasting C-peptide increased sign ificantly (214 +/- 11 pmol/L; P < 0.05) over the first 6 months in P. After the initial 6 months, ICA levels tended to decrease in all patie nts and were not detected after 60 months. GAD65-Ab levels were not in fluenced by plasmapheresis and, also in contrast to ICA, increased sig nificantly (P < 0.05) in the whole study population after 60 months. I n fact, 4 initially negative patients became GAD65-Ab positive after d iagnosis (in 2 patients >24 months after diagnosis). We conclude that plasmapheresis of newly diagnosed IDDM patients does not change subseq uent GAD65-Ab levels, but ICA are significantly decreased with associa ted improved C-peptide and HbA(1c) levels.